Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Rolfe LindseyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Rapaport RobynOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Laporte KathleenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Ehrlich Christopher BOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:572,182Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Corey DanielOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:856,671Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Carter Charles RossOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:395,387Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Byrnes MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Atwood Brian GOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,317,956Price:--
-
Feb 26, 2024 (filed on Feb 26, 2024)Insider Name:Corey DanielOwnership Type:Direct OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:Form 3/A : Amendment of a previous Form 3# or value acquired/disposed of:--Price:--
-
Feb 26, 2024 (filed on Feb 26, 2024)Insider Name:Corey DanielOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:Form 3/A : Amendment of a previous Form 3# or value acquired/disposed of:--Price:--
Filings by filing date
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Rolfe LindseyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Rapaport RobynOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Laporte KathleenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Ehrlich Christopher BOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:572,182Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Corey DanielOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:856,671Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Carter Charles RossOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:395,387Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Byrnes MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Atwood Brian GOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,317,956Price:--
-
Feb 14, 2024 (filed on Mar 11, 2024)Insider Name:Atwood Brian GOwnership Type:Indirect OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,857Price:--
-
Feb 14, 2024 (filed on Mar 11, 2024)Insider Name:Atwood Brian GOwnership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,002Price:$1,000.00
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 201 Haskins Way, Suite 230 SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.phoenixbiotechacquisitioncorp.com |
IR: | See website |
Key People | ||
Douglas Fisher President | Christopher B. Ehrlich Chief Executive Officer, Director | Daniel E. Geffken Chief Financial Officer |
Business Overview |
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company's proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies. |
Financial Overview |
For the fiscal year ended 31 December 2023, CERo Therapeutics Holdings Inc revenues was not reported. Net loss increased from $668K to $2.5M. Higher net loss reflects Interest income earned on marketable sec decrease of 83% to $492K (income), General and administrative increase of 2% to $2.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.03 to -$0.39. |
Employees: | 8 as of Apr 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $21.63M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$2.93M as of Dec 31, 2023 |
Net annual income (TTM): | -$2.54M as of Dec 31, 2023 |
Free cash flow (TTM): | -$1.52M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $1.46M as of Dec 31, 2023 |
Shares outstanding: | 19,319,815 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |